Sexual Dysfunction

A study of more than 300 men sheds new light on the prostate safety of testosterone replacement therapy.

Other products featured include: Radiosurgery collimator allows treatment of broad rang of tumors and Phi prostate cancer test and more.

Most health information seekers navigate the Internet for what they think will be the best information available about their health condition or that of a loved one. Unfortunately, the Internet is unfiltered, unregulated, and often saturated with promotional, unsubstantiated, and at times frightening information.

Patients taking to the Internet for information about testosterone replacement therapy are likely getting an incomplete picture of the potential risks and adverse effects linked with the treatment, say researchers from Northwestern University Feinberg School of Medicine, Chicago, and the University of Pennsylvania, Philadelphia.

Products in the pipeline for prostate cancer, bladder cancer, and much more.

Other products featured include a spacer system to protect men undergoing PCa radiotherapy, a pelvic floor exercise app, and more.

A newly published review suggests that age-related testosterone deficiency treatment with intramuscular injections of testosterone replacement therapy offers health benefits and lower cardiovascular risk compared to testosterone replacement by patch or gel.

Products in the pipeline for prostate cancer, bladder cancer, stress urinary incontinence, chronic prostatitis/chronic pelvic pain syndrome, hypoactive sexual desire disorder.

To help you maximize your AUA experience, Urology Times’ editorial board and other thought leaders have pored over hundreds of abstracts to identify the key trends and can’t-miss research from this year’s meeting.

Other highly read UT articles this month include a large comparison of robotic and open RP, answers to your questions about coding for prostate biopsy, and several studies about risks for low and high T.

A new testosterone nasal gel (Natesto) is safe and efficacious, according to phase III data presented at the Endocrine Society annual meeting in San Diego.

A handful of new studies reveal new information about risk factors for both low and high testosterone as well as the potential risks associated with each.

The FDA acted on recommendations from one of its advisory committees by requiring manufacturers of testosterone therapies to make label changes that restrict the drugs’ usage.

In the experience of Martin Miner, MD, and Joel Heidelbaugh, MD, men’s health is far more than the working relationship between urology and primary care centered around male-specific medical concerns, and includes several different and significant subspecialties.

A literature review has found no evidence that testosterone therapy increases cardiovascular risk.

New products and services from Samsung Electronics America, Syneron Medical, American Medical Systems, New Star, Buffalo Filter, Cook Medical, Endo International, Trimel BioPharma Metamark, and the National Comprehensive Cancer Network.

The 2015 omnibus spending bill canceled a $10 million appropriation for the Independent Payment Advisory Board (IPAB). Congress also approved a bill that cuts Medicare funding for vacuum erection systems. Rationing care, whether undertaken by the IPAB or Congress, must be opposed when it arbitrarily selects services based on public perception and not medical necessity, writes Ross E. Weber of the AACU.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

Urology Times continues its "Year in Review" series with a look at the most-read men's health articles of 2014.

Results of a randomized, double-blind, placebo-controlled, phase IV study provide further confirmation that the erectogenic effect of the phosphodiesterase-type-5 inhibitor avanafil (Stendra) has a quick onset.

Other products discussed in this article include a prosthesis for underactive bladder, a prostate cancer test, and an erectile dysfunction drug.

Long-term testosterone therapy in hypogonadal men appears to be safe and does not increase the risk of prostate cancer, according to a newly published analysis of three patient registries.

In separate actions, two pharmaceutical makers have acquired the rights to a novel testosterone agent and a patented formulation for interstitial cystitis/painful bladder syndrome.

The European Medicines Agency has issued new recommendations regarding testosterone replacement therapy after reviewing the cardiovascular risks of TRT. The recommendations were endorsed by a regulatory body that is responsible for the marketing authorization of drugs throughout Europe.

Testosterone replacement therapy reduced men’s overall risks for death, nonfatal myocardial infarction, and stroke, as well as for death alone in a study presented at the American Heart Association Scientific Sessions in Chicago.